Plasminogen activator inhibitor-1 (PAI-1) gene polymorphism (-675 4G/5G) associated with obesity and vascular in risk in children

Journal of Pediatric Endocrinology and Metabolism

Volumn 19, Issue 5, 2006, Pages 741-748

  Berberoǧlu, Merih ^a   Evliyaoglu O ^a   Adiyaman, P ^a   Ocal G ^a   Ulukol, B ^a   Simsek F ^a   Siklar Z ^a   Torel A ^a   Ozel D ^a   Akar, N ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Childhood obesity; PAI 1 gene polymorphism; Vascular disease

Indexed keywords

GLUCOSE; INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ACANTHOSIS NIGRICANS; ADOLESCENT; ARTICLE; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CHILD; CLINICAL FEATURE; CONFIDENCE INTERVAL; CONTROLLED STUDY; EPIDEMIOLOGICAL DATA; FAMILIAL DISEASE; FAMILY HISTORY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; GLUCOSE BLOOD LEVEL; HETEROZYGOTE; HOMEOSTASIS; HOMOZYGOSITY; HUMAN; HYPERTRIGLYCERIDEMIA; INCIDENCE; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT REFERRAL; PREVALENCE; RISK FACTOR; SOCIOECONOMICS;

ADULT; ALLELES; BLOOD GLUCOSE; BODY MASS INDEX; CHILD; GENE FREQUENCY; HUMANS; HYPERINSULINISM; INSULIN; METABOLIC SYNDROME X; OBESITY; ODDS RATIO; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; RISK FACTORS; TREATMENT OUTCOME; VASCULAR DISEASES;

EID: 33745250147     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Reaven G. Syndrome X, 10 years after. Drugs 1999; 58: 19-20.
2. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689.
3. Mertens I, Van Gaal LF. Obesity, hemostasis and the fibrinolytic system. Obes Rev 2002; 3: 85-101.
4. von Kandel R, Maly FE, Frey K, Fischer JE. Contribution of the type 1 plasminogen activator inhibitor 4G/5G gene polymorphism to impaired fibrinolysis n vital exhaustion. Ital Heart J 2003; 4: 791-796.
5. Juhan-Vague I, Alessi MC, Mavri A, Morange PE. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 2003; 1: 1575-1579.
6. Schafer K, Fujisawa K, Konstantinides S, Loskutoff DJ. Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice. FASEB J 2001; 15: 1840-1842.
7. Eriksson P, Kallin B, van't Hooft FM, Bavenholm P, Hamsten. A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor I gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995; 92: 1851-1855.
8. Hoffstedt J, Andersson IL, Persson L, Isaksson B, Arner P. The common -675 4G/5G polymorphism in the plasminogen activator inhibitor -1 gene is strongly associated with obesity. Diabetologia 2002; 45: 584-587.
9. Yilmaz E, Akar E, Akar N. Effect of plasminogen activator inhibitor-1 4G/ 5G polymorphism in Turkish deep vein thromboembolic patients with and without prothrombin 20210 G→A. Turk J Haematol 2004; 21: 83-86.
10. Sartori MT, Wiman B, Vettore S, Dazzi F, Girolami A, Patrassi GM. 4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis. Thromb Haemost 1998; 80: 956-960.
11. Roest M, van der Schouw YT, Banga JD, Tempelman MJ, de Groot PG, Sixma JJ, Grobbee DE. Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women. Circulation 2000; 101: 67-70.
12. Troiano RP, Flegal KM, Kuczmarski RJ, Campbell SM, Johnson CL. Overweight prevalence and trends for children and adolescents. The National Health and Nutrition Examination Surveys, 1963 to 1991. Arch Pediatr Adolesc Med 1995; 149: 1085-1091.
13. Tritos NA, Mantzoros CS. Clinical review 97: Syndromes of severe insulin resistance. J Clin Endocrinol Metab 1998; 83: 3025-3030.
14. Haffner SM, Kennedy E, Gonzalez C, Stern MP, Miettinen H. A prospective analysis of the HOMA model. The Mexico City Diabetes Study. Diabetes Care 1996; 19: 1138-1141.
15. Tümer N, Yalçinkaya F, Ince E, Ekim M, Köse Çakar N, Kara N, Özkaya N, Ensari C, Önder S. Blood pressure nomograms for children and adolescents in Turkey. Pediatr Nephrol 1999; 13: 438-443.
16. Akar N, Yilmaz E, Akar E, Avcu F, Yalcin A, Cin S. Effect of plasminogen activator inhibitor-1 4G/5G polymorphism in Turkish deep vein thrombotic patients with and without FV1691 G→A. Thromb Res 2000; 97: 227-230.
17. Moreno LA, Sarria A, Fleta J, Rodriguez G, Bueno M. Trends in body mass index and overweight prevalence among children and adolescents in the region of Arason (Spain) from 1985 to 1995. Int J Obes Relat Metab Disord 2000; 24: 925-931.
18. Val S, Tichet J, Rolland-Cachera MF. Trends in the prevalence of obesity between 1980 and 1996 among French adults and children. Int J Obes Relat Metab Disord 1998; Suppl 3: S210.
19. D'Argenio P, Citarelle A, Palombi EL, Aver Samo MP, Bassi R, Di Fiore A, Feri M, Glielmo N, Iglio G, Petroccia C, Sasso L, Sasso S. Obesity and overweight among pre-adolescents: a study from the Province of Bebevento. BEN 2001; 14: 3-5.
20. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM; Insulin Resistance Atherosclerosis Study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002; 51: 1131-1137.
21. Ma LJ, Mao SL, Taylor KL, Kanjanabuch T, Guan Y, Zhang Y, Brown NJ, Swift LL, McGuinness OP, Wasserman DH, Vaughan DE, Fogo AB. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 2004; 53: 336-346.